| Hans-Günter Meyer-Thompson | Buprenorphin
18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
Rutrick D, Learned SM, Boyett B, Hassman D, Shinde S, Zhao Y.
J Subst Use Addict Treat. 2023 Aug 30;154:209155. doi: 10.1016/j.josat.2023.209155. Epub ahead of print. PMID: 37657559.
https://www.sciencedirect.com/science/article/pii/S2949875923002060